Product distribution

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Retrieved on: 
Wednesday, January 11, 2023

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.

Key Points: 
  • Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.
  • CH Trading Group will act as the exclusive territories distributor of Celularity’s previously announced Halal-Certified products within more than 100 countries.
  • The Product Distribution Agreement for Celularity’s Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
  • “Based on market demand for Celularity’s commercial biomaterial products, we believe there is a billion-dollar commercial opportunity across the Middle East North Africa Islamic markets,” said Sayed Zayan, CEO of CH Trading Group.

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Retrieved on: 
Wednesday, January 11, 2023

FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement. CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.   

Key Points: 
  • Relationship opens access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products across the Middle East and the broader Islamic world
    FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.
  • CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries.
  • The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
  • "Based on market demand for Celularity's commercial biomaterial products, we believe there is a billion-dollar commercial opportunity across the Middle East North Africa Islamic markets," said Sayed Zayan,  CEO of CH Trading Group.

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Retrieved on: 
Wednesday, January 11, 2023

FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement. CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.   

Key Points: 
  • Relationship opens access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products across the Middle East and the broader Islamic world
    FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.
  • CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries.
  • The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
  • "Based on market demand for Celularity's commercial biomaterial products, we believe there is a billion-dollar commercial opportunity across the Middle East North Africa Islamic markets," said Sayed Zayan,  CEO of CH Trading Group.

The Worldwide Anticoagulant Reversal Drugs Industry is Expected to Reach $1.6 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022

The Global Anticoagulant Reversal Drugs Market is estimated to be worth USD 807.2 million in 2022, and is expected to reach USD 1,616.52 million by 2027, growing at a CAGR of 14.9%.

Key Points: 
  • The Global Anticoagulant Reversal Drugs Market is estimated to be worth USD 807.2 million in 2022, and is expected to reach USD 1,616.52 million by 2027, growing at a CAGR of 14.9%.
  • The Global Anticoagulant Reversal Drugs Market is segmented based on Products, Distribution, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Anticoagulant Reversal Drugs Market.
  • The report offers a comprehensive evaluation of the Global Anticoagulant Reversal Drugs Market.

ClarionDoor Aligns Product Suite to Market Demand

Retrieved on: 
Tuesday, February 22, 2022

SANTA BARBARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- ClarionDoor, a Zywave company (ClarionDoor) , is pleased to announce a strategic repositioning of the companys entire product suite to better align with market demand.

Key Points: 
  • SANTA BARBARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- ClarionDoor, a Zywave company (ClarionDoor) , is pleased to announce a strategic repositioning of the companys entire product suite to better align with market demand.
  • This shift in positioning moves the ClarionDoor products, including standalone rating, comparative rating, product distribution, and policy management, away from complex naming conventions to enable insurers, managing general agents (MGAs), and program administrators to more effectively find solutions that solve challenges.
  • The insurance industry is over-saturated with technology products hidden behind vague naming conventions that dont align with their function, said Michael DeGusta, general manager at ClarionDoor .
  • Founded in 2010 and acquired by Zywave in 2021, ClarionDoor has been known in the insurance industry as a trailblazer providing cloud-only, API-architected insurance technology.